ストックスクリーナーアプリを入手
4.65
1.53%
0.07
プレマーケット:
4.65
前日終値:
$4.58
開ける：
$4.56
24時間の取引高:
346.28K
Relative Volume:
0.12
時価総額：
$58.78M
収益：
-
当期純損益:
$-30.54M
株価収益率:
-3.00
EPS:
-1.55
ネットキャッシュフロー:
$-18.30M
1週間 パフォーマンス:
-11.43%
1か月 パフォーマンス:
+577.15%
6か月 パフォーマンス:
+650.00%
1年 パフォーマンス:
+959.23%
1日の値動き範囲:
$4.50
$4.68
1週間の範囲:
$4.44
$5.26
52週間の値動き範囲:
$0.202
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.65 | 67.03M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Guggenheim | Buy |
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
Is Unicycive Therapeutics Inc. a good long term investmentAccelerated profit realization - Jammu Links News
What drives Unicycive Therapeutics Inc. stock priceConsistently profitable trades - Jammu Links News
Why Unicycive Therapeutics Inc. stock is on top investor watchlistsRisk Aware High Growth Picks - Newser
Why Unicycive Therapeutics Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Newser
How Unicycive Therapeutics Inc. stock performs during market volatilityReal Chart Play - Newser
What makes Unicycive Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Transcript : Unicycive Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 11 - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc.UNCY - WV News
Unicycive regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Unicycive regains Nasdaq compliance after reverse stock split - Investing.com
Unicycive Therapeutics Regains Compliance with Nasdaq Listing Standards Following Share Price Recovery - Quiver Quantitative
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Unicycive Successfully Maintains Nasdaq Listing Following 1:10 Reverse Stock Split - Stock Titan
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Unicycive Therapeutics to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference - Nasdaq
Clinical-Stage Kidney Disease Biotech Unicycive Reveals Latest Therapeutic Progress at Major Healthcare Conference - Stock Titan
Unicycive Therapeutics - The Pharma Letter
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
Ongoing Securities Investigation Into Unicycive Therapeutics, Inc. (UNCY)Contact Levi & Korsinsky - ACCESS Newswire
Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com India
Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
H.C. Wainwright keeps Buy on Unicycive Therapeutics , says CRL ‘anticipated’ - TipRanks
Unicycive stock falls after FDA issues Complete Response Letter By Investing.com - Investing.com Nigeria
Unicycive stock falls after FDA issues Complete Response Letter - Investing.com Australia
Does Unicycive Therapeutics Inc (NASDAQ: UNCY) Still Need To Convince Analysts? - Stocksregister
Unicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down – What’s Next? - Defense World
Unicycive Therapeutics to execute 1-for-10 reverse stock split - MSN
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing By Investing.com - Investing.com South Africa
Unicycive Therapeutics to Implement 1-for-10 Reverse Stock Split - MarketScreener
Unicycive Therapeutics (UNCY) Announces 1-for-10 Reverse Stock S - GuruFocus
Unicycive to implement 1-for-10 reverse stock split to regain Nasdaq listing - Investing.com
Unicycive Therapeutics Announces Reverse Stock Split - marketscreener.com
Unicycive Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
Kaplan Fox Alerts Investors of Unicycive Therapeutics to an Investigation of Possible Securities Law Violations - FinancialContent
Equities Analysts Offer Predictions for UNCY Q3 Earnings - Defense World
Unicycive drops after FDA finds drug manufacturing issues - MSN
Kaplan Fox is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - The Globe and Mail
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m - Yahoo Finance
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy By Investing.com - Investing.com South Africa
Kaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations - FinancialContent
Unicycive Therapeutics Stock: FDA Halts Progress on Key Drug - sharewise
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues - Investing.com Australia
Unicycive Therapeutics Stock Is Trading Lower Tuesday: What's Going On? - Benzinga
Unicycive Therapeutics stock tumbles after FDA flags manufacturing issues By Investing.com - Investing.com Nigeria
Insmed’s stock rallies on PAH data; Unicycive aims to resolve CDMO issues - Endpoints News
UNCY Stock Drops Amid FDA Manufacturing Deficiencies - GuruFocus
Unicycive Says US FDA Inspection Reveals Manufacturing Deficiencies for Oxylanthanum Carbonate Drug Candidate; Shares Down - MarketScreener
FDA flags issues at drug manufacturer for Unicycive’s kidney therapy - Investing.com Australia
Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia - marketscreener.com
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):